Glenmark to use Rs 296 crore loan for debt refinance, capex
The IFC has committed an unsecured loan of $40 million to the company.
Chennai: Pharma major Glenmark Pharmaceuticals Ltd will be utilising the $40 million loan from International Finance Corporation (IFC) to refinance existing debt and for capital expenditure.
Glenmark is having a good presence in generics, over the counter and specialty drugs.
The IFC has committed an unsecured loan of $40 million to the company.
Queried about the deployment of the loan fund a company spokesperson told IANS: "The $40 mn loan will be utilized to refinance existing Foreign Currency Convertible Bonds (FCCBs) and capex funding."
The IFC in 2016 had invested in convertible debt of $75 million in Glenmark for expansion project.
Read also: Glenmark gets Rs 290 crore COVID credit line from IFC
According to the Glenmark spokesperson, IFC had subscribed to the company's FCCB for a principal of $75 million.
"The FCCB's have maturity in June 2022 and are not yet converted," the official said.
Read also: Glenmark secures CDSCO panel nod for manufacturing, marketing acne drug Tazarotene
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.